
Higher patient cost-sharing is associated with a lower likelihood of treatment augmentation in patients with depression who are treated with antidepressants.
Higher patient cost-sharing is associated with a lower likelihood of treatment augmentation in patients with depression who are treated with antidepressants.
Prior authorization for pregabalin in commercial insurance plans accomplished the objective of lower pregabalin utilization; however, there was no significant decrease in disease-related healthcare costs.
Published: June 10th 2010 | Updated:
Published: January 16th 2012 | Updated:
259 Prospect Plains Rd, Bldg H
Monroe, NJ 08831
© 2025 MJH Life Sciences®
All rights reserved.